Tele: 561.316.3330
Breaking Medical Device News

Wednesday, September 22, 2021
HomeKalium DiagnosticsNew British Company: Develops the First Home Use Blood Potassium Test Kit

New British Company: Develops the First Home Use Blood Potassium Test Kit

A fast, accurate and low-cost test for blood potassium levels, which can be used at home and has the potential to improve the safety, health, and lifestyle of tens of millions of people worldwide, is being developed by Kalium Diagnostics.

Kalium, a Cambridge University spin-out company has won the £25,000 Armourers & Brasiers Venture Prize to support the commercialization of its materials science research.

Kidney diseases, as well as heart disease and treatments for high blood pressure, can be associated with potentially dangerous abnormalities of bodily potassium levels. Maintenance of potassium levels, within defined limits, is crucial to health as severe high or indeed low potassium can lead to heart rhythm abnormalities and sudden death.

“Currently, there is no medically approved, accurate blood potassium test available for use outside of a hospital or centralized lab settings,” explained Professor Fiona Karet, a co-founder of Kalium, and professor of nephrology at the University of Cambridge. “This deprives millions of people with renal or cardiovascular conditions, and their healthcare teams, of the opportunity to monitor and improve their health and well-being.”

“This ‘home test’ idea originated from patients at Addenbrooke’s Hospital who were asked to monitor their own blood potassium levels,” said Professor Karet. “We took this on board and are now developing a test-kit that enables blood electrolyte measurement in a small fingerprick drop of blood.”

The Kalium test kit will function in a similar way to a glucometer commonly used by diabetics. It will comprise an electronic reader linked to a smartphone, plus a single use disposable test-strip. This kit will be used by patients themselves, giving them the type of control over their lives and diets that millions of diabetics have enjoyed for decades. It can also be used by GPs and specialists who need a quick and convenient check of the patient’s potassium to better manage clinical decisions. And, also companies developing new medicines could benefit from having the device available in clinical trials.

The platform technology is based on miniaturized electrochemical sensing and will enable both healthcare providers and patients to obtain results instantly with hospital-grade accuracy at the point-of-care or at home. This will allow them to take action to reduce health risks.

“In the community, patients are currently dependent on trips to a hospital or community blood-taking services and centralized lab-based testing, and these are associated with inconvenience and a delay in obtaining results,” explained Professor Karet.

Patient groups which can be expected to benefit most from a new home test include dialysis and pre-dialysis chronic kidney disease patients, as well as those with inherited kidney disorders. Others include renal transplant recipients on immunosuppressants as well as some patients with severe eating disorders and intestinal failure as well as up to 25million patients worldwide on commonly-used medications such as ACE inhibitors or diuretics, which affect potassium.

Kalium, was launched last year with the project originating at the University of Cambridge, in a collaborative effort between researchers in the Cambridge Institute for Medical Research and the Department of Chemistry.

“The £25,000 prize will help buy critical equipment needed to address key technical challenges in commercializing the research,” said Professor Bill Bonfield CBE FRS, chairman of the Armourers and Brasiers Venture Prize judging panel. “Our prize looks to encourage scientific entrepreneurship in the UK and provides funding to help innovative developments like this realize their potential.”

The main initial funding that enabled the work to get off the ground came to the University of Cambridge from Kidney Research UK, with other contributions from Addenbrooke’s Kidney Patients’ Association, Addenbrooke’s Charitable Trust, Cambridge Enterprise, the Babraham Accelerator program, Accelerate Cambridge and The Wellcome Trust Developing Concept Fund.

Medical Device News Magazine
Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

Stay Connected


Don't Miss

Kleiner Device Labs Receives FDA Market Clearance for KG2 Surge Flow-Thru Interbody System

The system maximizes total bone graft delivery volume, better distributes graft bilaterally into the intervertebral disc space, and streamlines the implant delivery, positioning, and grafting process for TLIF and PLIF spinal fusion procedures.

Matthew Cranfill New ExtriCARE USA Director Of Clinical Services

"Matt's impressive experience and skillset easily made him our top pick," said Peter Mason, President of ExtriCARE USA.

FDA Authorizes Software that Can Help Identify Prostate Cancer

The software is called Paige Prostate and is compatible for use with slide images that have been digitized using a scanner.

Shannon Lantzy MedCrypt New VP of Consulting

"I met Shannon at a healthcare-related event several years ago and was immediately impressed with her passion and drive to move healthcare into a digital future," said Mike Kijewski, CEO of MedCrypt.

Mark Foster Joins Xenocor BOD

Foster is a versatile and visionary C-Suite executive who brings 20 years of general management and leadership experience from both venture-backed growth-stage organizations and world-class medical device companies

Hinge Health Acquires the Most Advanced Computer Vision Technology for Tracking Human Motion

CEO Daniel Perez explained, “We won’t stop investing in technology to deliver the most patient-centered digital clinic that improves member experience and outcomes while reducing costs. wrnch allows us to take a giant leap forward in all respects.”

Dale W Wood Congratulates the Huma Team on Raising $130 Million

Major health and technology companies across the world have committed upwards of $130 million to Huma Therapeutics, the health-tech company backed by Dale Ventures.

Rhaeos Awarded $4 Million NIH SBIR Grant

Under the NIH SBIR grant, Rhaeos will leverage their existing wireless sensor hardware to provide additional quantitative flow data to the clinician, giving insight into this currently inaccessible and highly relevant shunt performance metric.

By using this website you agree to accept Medical Device News Magazine Privacy Policy